In Vitro Tissue Stem Cell Toxicity Screening Method
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack direct pre-clinical assays for tissue stem cell toxicity, relying on animal models that are expensive and poor predictors of human toxicity, due to the difficulty in isolating and purifying tissue stem cells, which are a minute fraction of human tissue cell preparations, and the lack of specific biomarkers for drug toxicity testing.
Innovation Solution
A method involving a unique culturing schedule with sequential passages based on time intervals and consistent dilution factors, allowing for the monitoring of tissue stem cells, transient cells, and terminal cells, enabling the determination of an agent's toxic or positive effects on these cell types without the need for animal testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tissue stem cells are isolated from human tissue cell preparations, then direct pre-clinical assays for tissue stem cell toxicity can be performed, but tissue stem cells are a minute fraction of the preparation making isolation difficult
Solution Approach 1:
The patent segments the heterogeneous cell population into distinct kinetic groups (tissue stem cells, transient cells, terminal cells) by monitoring their differential proliferation and differentiation behaviors over time in culture, allowing indirect identification and assessment of tissue stem cells without physical isolation
Solution Approach 2:
The patent uses cell kinetic parameters (proliferation rate, differentiation rate, population doublings) as intermediary measurements to indirectly assess tissue stem cell presence and toxicity effects, rather than directly measuring or isolating the rare stem cells themselves
2Reliability
If animal models are used for pre-clinical toxicity testing, then tissue stem cell toxicity can be evaluated indirectly, but animal models are expensive and poor predictors of human toxicity
Solution Approach 1:
The patent creates an in vitro copy of human tissue stem cell kinetics and responses to toxicants, using cultured human cells that replicate the hierarchical cell kinetics architecture, providing a human-relevant model that is cheaper and more reliable than animal models
Solution Approach 2:
The patent uses disposable cell culture systems with relatively short cultivation periods to assess toxicity, replacing expensive and time-consuming animal models with affordable in vitro assays using human cell cultures
3Productivity
If conventional passaging schedules are used for cell cultures, then cell cultures can be maintained, but the cell population reaches a point of containing only terminally differentiated cells too slowly to monitor all three cell types
Solution Approach 1:
The patent implements periodic passaging at fixed time intervals rather than based on confluency, creating a structured sampling regime that captures the kinetic transitions of all three cell types before the population becomes dominated by terminal cells
Solution Approach 2:
The patent changes the passaging parameters (fixed time intervals, specific dilution factors) to accelerate the progression through cell kinetic stages, allowing complete monitoring of tissue stem cells, transient cells, and terminal cells within a shorter time frame
Data Source
AI summary
Herein, we describe a direct in vitro method that identifies agents that are toxic against natural human tissue stem cells. We provide a novel schedule for culturing any cell population containing homologous tissue stem cells that allows the number and cell kinetics of tissue stem cells, transient cells, and terminally differentiated cells within the population to be monitored. Using the passage schedule together with determination of a growth curve for the population, one can determine whether or not an agent is toxic to tissue stem cells, or to transient cells and/or terminal cells. The same method can also be used to identify agents that act positively on tissue stem cells and the other specific cell types.